How Much Does Reclast (Zoledronic Acid) Cost in Florida in 2026?

Florida Retail Pricing Breakdown

The average cash-pay price for a single 5 mg zoledronic acid infusion across Florida outpatient facilities in 2026 sits near $600, though prices range from $350 at high-volume generic infusion centers to $1,500 or more at hospital outpatient departments billing the Novartis brand product. This price includes the drug cost, saline vehicle, IV supplies, and nursing administration time.

Generic zoledronic acid (available since FDA approval of the first generic in 2013) accounts for most dispensed volume. The original Reclast NDA was granted to Novartis in 2007 for postmenopausal osteoporosis treatment, and the brand carries a wholesale acquisition cost near $1,500 per dose. Florida patients paying cash should request the generic HCPCS code J3489 when scheduling at physician offices or ambulatory infusion suites.

Hospital outpatient departments in Florida commonly apply facility fees that double or triple the drug acquisition cost. A 2022 JAMA analysis found that hospital outpatient drug administration charges averaged 4.1 times higher than physician office charges for the same injectable drugs. Selecting a physician-office or freestanding infusion center eliminates this markup.

Medicare Part B Coverage in Florida

Medicare Part B covers zoledronic acid for osteoporosis treatment and prevention as a physician-administered injectable under the Part B drug benefit. After the annual Part B deductible ($257 in 2025), beneficiaries owe 20% coinsurance on the Medicare-allowed amount. For generic zoledronic acid billed at the average sales price (ASP + 6%), the out-of-pocket coinsurance typically falls between $30 and $80 per infusion.

Medicare Advantage plans in Florida (including Humana, UnitedHealthcare, and Aetna plans prevalent in South Florida) must cover Part B drugs at minimum original Medicare levels, though network restrictions and prior authorization requirements vary by plan. The HORIZON-PFT trial (N=7,765) demonstrated that once-yearly zoledronic acid reduced morphometric vertebral fractures by 70% over 3 years (RR 0.30 to 95% CI 0.24-0.38), establishing the efficacy evidence that CMS uses for coverage determinations.

Florida has 4.8 million Medicare beneficiaries, the second-highest state enrollment nationally. Patients utilizing traditional Medicare with a Medigap supplement (Plans F or G) will have the 20% coinsurance covered entirely by the supplement, reducing their net cost to $0 beyond the annual deductible.

Florida Medicaid Limitations

Florida Medicaid does not cover zoledronic acid for osteoporosis. Coverage is restricted to oncology-related indications (bone metastases, hypercalcemia of malignancy). This exclusion applies to both fee-for-service Medicaid and Florida's Statewide Medicaid Managed Care plans, including Sunshine Health, Molina, and Humana Healthy Horizons.

Dual-eligible patients (those enrolled in both Medicare and Medicaid) can still access zoledronic acid through their Medicare Part B benefit. The Medicare Savings Program covers Part B premiums and cost-sharing for qualified beneficiaries with incomes below 135% of the federal poverty level, effectively making the infusion free for this population.

For Medicaid-only patients needing osteoporosis treatment, alternative covered agents typically include oral bisphosphonates (alendronate, risedronate) and denosumab (Prolia), which demonstrated 68% vertebral fracture risk reduction in the FREEDOM trial (N=7,868). Florida Medicaid preferred drug lists should be checked quarterly, as formulary changes occur during each review cycle.

Commercial Insurance Coverage

Most commercial insurers in Florida cover zoledronic acid for FDA-approved indications with standard prior authorization requirements. Typical criteria include documented T-score of -2.5 or below on DXA scan, or history of fragility fracture, consistent with NOF/Endocrine Society guidelines.

Common prior authorization requirements across Florida's major carriers (Blue Cross Blue Shield of Florida, Aetna, Cigna, UnitedHealthcare):

• DXA-confirmed osteoporosis or osteopenia with FRAX score exceeding treatment threshold
• Trial of or contraindication to oral bisphosphonate therapy (typically one documented attempt)
• Prescriber attestation confirming no contraindications (estimated GFR must exceed 35 mL/min)

The renal threshold is clinically significant. The Reclast prescribing information contraindicates use in patients with creatinine clearance <35 mL/min due to increased risk of renal deterioration observed in clinical trials. A post-marketing analysis confirmed acute-phase reactions occur in approximately 32% of first-time recipients but drop to 7% with subsequent infusions.

Step therapy requirements vary. UnitedHealthcare Florida plans often require 90-day trial of alendronate or risedronate before authorizing zoledronic acid. BCBS Florida Commercial plans may waive step therapy with documented GI intolerance, esophageal stricture, or inability to remain upright for 30 minutes post-dose.

Compounded Zoledronic Acid in Florida

Compounded zoledronic acid is legal in Florida through licensed 503A pharmacies operating under strict Florida Board of Pharmacy oversight. Section 503A of the Federal Food, Drug, and Cosmetic Act permits patient-specific compounding by state-licensed pharmacies when a valid prescription exists.

Florida's regulatory framework requires 503A compounding pharmacies to maintain current state licensure, compound only in response to individual prescriptions, use USP-grade ingredients, and follow USP <797> sterile compounding standards. Zoledronic acid is a sterile injectable, placing it in the highest-risk compounding category requiring ISO 5 cleanroom environments and beyond-use dating protocols.

Cost savings from 503A compounding can be substantial. Some Florida compounding pharmacies offer zoledronic acid 5 mg infusions at $150-$250 total (drug plus compounding fee), representing 60-75% savings versus generic retail pricing. Patients must still arrange separate infusion administration services.

Important caveats exist. Compounded drugs are not FDA-approved products. They lack the bioequivalence testing, stability data, and manufacturing oversight of FDA-approved generics. The FDA's 2023 advisory emphasizes that compounded medications should be used only when a commercially available product does not meet a patient's medical needs.

Telehealth Prescribing in Florida

Florida permits telehealth prescribing of zoledronic acid for initial osteoporosis evaluation and treatment decisions. The Florida Telehealth Act (F.S. 456.47) allows any Florida-licensed physician to establish a patient relationship via synchronous audio-video communication and prescribe medications based on that evaluation.

A telehealth visit can generate the prescription, but administration still requires an in-person infusion appointment. Practical workflow for Florida patients: complete a telehealth consultation with a board-certified endocrinologist or rheumatologist, receive the prescription, then schedule the infusion at a local outpatient center.

DXA scan results must be available for review during the telehealth visit. The ISCD 2019 Official Positions recommend central DXA (hip and spine) as the reference standard for osteoporosis diagnosis, and most prescribers require imaging performed within the preceding 24 months before initiating bisphosphonate therapy.

Discount Programs and Patient Assistance

Several programs reduce zoledronic acid costs for Florida patients. The Novartis Patient Assistance Foundation offers free brand Reclast to uninsured patients with household income below 500% of the federal poverty level ($75,300 for a single individual in 2025). Applications require documentation of income, insurance status, and prescriber signature.

For commercially insured patients, manufacturer copay cards can reduce out-of-pocket costs to $0 on brand Reclast, though these programs exclude Medicare, Medicaid, and other government-payer beneficiaries per federal anti-kickback statute requirements.

Additional Florida-specific resources include county health departments offering discounted infusion services in Miami-Dade, Broward, and Hillsborough counties for qualifying residents. The AACE 2020 osteoporosis guidelines classify zoledronic acid as a first-line agent for high-fracture-risk patients, supporting medical necessity arguments for insurance appeals when initial authorization is denied.

GoodRx, RxSaver, and similar aggregators show Florida cash prices for generic zoledronic acid 5 mg/100 mL ranging from $287 to $640 depending on facility. These prices reflect the drug acquisition cost only. Administration fees (CPT 96365 for first-hour IV infusion, typically $75-$200) are billed separately.

Clinical Value Context for Cost Decisions

Zoledronic acid's once-yearly dosing offers adherence advantages that directly affect its cost-effectiveness. A 2012 systematic review in Osteoporosis International found that oral bisphosphonate persistence at 12 months averages only 40-50%, while injectable agents achieve 80-90% adherence by design because administration occurs in a clinical setting.

The HORIZON Recurrent Fracture Trial demonstrated that zoledronic acid given within 90 days of hip fracture repair reduced all-cause mortality by 28% over a median 1.9-year follow-up (HR 0.72 to 95% CI 0.56-0.93, P=0.01). This mortality benefit is unique among osteoporosis therapies and strengthens the argument for insurance coverage.

From a pharmacoeconomic standpoint, the annual cost of one zoledronic acid infusion ($600 cash, less with insurance) compares favorably to denosumab ($1,800-$2,400/year for twice-yearly injections) and romosozumab ($22,000-$26,000/year). The 2023 ASBMR Task Force report on secondary fracture prevention endorsed zoledronic acid as a cost-effective first-line therapy in treatment-naive patients with high fracture risk.

For patients requiring long-term therapy, bisphosphonate holidays after 3-5 years of zoledronic acid (per 2022 Endocrine Society guidelines) further reduce cumulative cost compared to medications requiring continuous administration.

Choosing the Lowest-Cost Option in Florida

The cheapest route depends on insurance status. Medicare beneficiaries with Medigap supplements pay $0. Commercially insured patients with copay cards also pay $0. Uninsured patients should compare physician-office generic pricing (typically $350-$500 all-inclusive) against 503A compounding options ($150-$250 drug cost plus $75-$150 administration fee at a separate infusion center).

Patients should request an itemized pre-service estimate under the No Surprises Act good-faith estimate requirement, which applies to uninsured and self-pay patients at all Florida facilities. This estimate must include the drug cost, facility/administration fee, and any ancillary charges (pre-infusion labs, saline, acetaminophen pre-medication).

Florida patients with annual household incomes under $40,000 who lack adequate insurance should apply simultaneously to the Novartis Patient Assistance Foundation and explore 503A compounding while awaiting determination. Average application processing takes 4-6 weeks, and zoledronic acid's once-yearly dosing means timing is flexible within a 2-3 month window without compromising fracture protection, based on bone turnover marker data showing sustained suppression for 12+ months post-infusion.